Researchers have published the results of a clinical trial evaluating the efficacy of an immunotherapy drug in treating a particularly aggressive form of lung cancer. Tarlatamab produced promising results, demonstrating antitumor activity and improving survival rates in patients for whom previous treatments hadn’t worked.
English (US) ·